Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") today announced that Ono submitted ...

Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in ...

– Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025 – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...

WALTHAM, Mass.-- (BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

ONO Pharmaceutical (OTCPK:OPHLY) to acquire all outstanding shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) for $25.60 per share in cash through a tender offer, resulting in an equity value of ...